GENELINK IS LARRY OAKELY'S SMALL-CAP PICK
August 20, 2002

Margate, NJ, August 20, 2002-GeneLink BioSciences, Inc. (OTCBB:GNLK) is featured in "Larry Oakley's Small-Cap Pick" editorial column at www.Small-CapTrader.com. Oakley has been covering small-cap companies for over 25 years in various capacities. 

Oakley said, "I've been following and writing about GNLK since June, 2000. I'm pleased to be able to report that its R&D efforts are paying off. GNLK is progressing fast. Of greatest importance-GNLK just graduated from an R&D firm to a revenue producing firm. It is shipping its first orders for its' do-it-yourself DNA Collection Kits® for nutragenetic profiling this month. One of the customers, MedQuest Pharmacy of Midvale, Utah, executed its "Letter of Intent" on 7/8/02. It followed up with its first order on 7/25/02. MedQuest is not an ordinary pharmacy but a "compounding pharmacy" that provides health care practitioners with state-of-the-art diagnostic services, customized pharmaceutical and nutraceutical products. It serves a growing international base of over 1,500 active healthcare professionals with over 20,000 patients by blending time-honored, individual formulation techniques with modern medical knowledge and quality control." 

He added: "On 8/15/2002, GNLK announced the appointment of leading cardiovascular surgeon Robert J. Schwarzberg, M.D., F.A.C.C. as a medical consultant. Dr. Schwarzberg, a board certified cardiologist, & a fellow of the American College of Cardiology, has been a leader in the telemedicine industry since 1989. He says: '...GeneLink's technology may forever change the way consumers choose nutritional supplements & skin care products.' This is just the latest example of the type of professionals & scientists who are flocking to GNLK. When such big names come aboard, it's a good indication of the value of the technology & the probable success of the company they join." 

About Small-CapTrader: Small-CapTrader is the sister site to www.WallStreetCorner.com, which was formed three years ago as a venue for Larry Oakley's Conservative Speculator newsletter, published since 1987. Small-CapTrader is now regularly read by investors in 61 countries. 

About GeneLink BioSciences, Inc.: GNLK is positioned to become a leading provider of genetic profiling technologies. It developed a proprietary method for "genetic profiling" (patents pending) & will begin licensing this breakthrough technology to companies that market or manufacture products for the $100 billion plus nutraceutical, skin care, wellness, & weight-loss industries. GNLK's DNA Collection Kit® is patented and has been reviewed by the FDA. Its DNA bank is located at the University of North Texas Health Science Center at Fort Worth, a 105-year-old medical facility that guarantees the DNA storage. For more information about GeneLink, visit its website at www.genelink.info.

Forward-Looking Statements: This press release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise.

SOURCE: GeneLink BioSciences, Inc.